(Q44101930)

29 November 2017

Biological activity of anastrozole in postmenopausal patients with advanced breast cancer: effects on estrogens and bone metabolism (English)

1 reference

29 November 2017

1 reference

1 reference

2

1 reference

29 November 2017

7

1 reference

29 November 2017

E Bajetta

1

1 reference

29 November 2017

N Zilembo

3

1 reference

29 November 2017

P Pozzi

4

1 reference

29 November 2017

I La Torre

5

1 reference

29 November 2017

L Ferrari

6

1 reference

29 November 2017

R Longarini

8

1 reference

29 November 2017

G Salvucci

9

1 reference

29 November 2017

E Bombardieri

10

1 reference

29 November 2017

1 July 2002

1 reference

29 November 2017

1 reference

29 November 2017

13

1 reference

29 November 2017

7

1 reference

29 November 2017

1059-1066

1 reference

Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: results of overview analysis of two phase III trials. Arimidex Study Group.

29 November 2017

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDF083

Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomized double-blind trial. The Exemestane Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDF083

Arimidex: a potent and selective fourth-generation aromatase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDF083

A randomized, open, parallel-group trial to compare the endocrine effects of oral anastrozole (Arimidex) with intramuscular formestane in postmenopausal women with advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDF083

The third-generation non-steroidal aromatase inhibitors: a review of their clinical benefits in the second-line hormonal treatment of advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDF083

Endocrinological and clinical evaluation of exemestane, a new steroidal aromatase inhibitor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDF083

The minimal effective exemestane dose for endocrine activity in advanced breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDF083

Serum concentration of the cross-linked carboxyterminal telopeptide of type I collagen (ICTP) is a useful prognostic indicator in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDF083

Type I collagen degradation product (ICTP) gives information about the nature of bone metastases and has prognostic value in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDF083

21 January 2018

Identifiers

DOI

10.1093/ANNONC/MDF083

1 reference

29 November 2017

1 reference